ライフサイエンスコーパス: polycytidylic acid

1 ith TLR ligands (Pam3CSK4, LPS, polyinosinic-polycytidylic acid).

2 etic MDA5 agonist/(ds)RNA mimic polyinosinic-polycytidylic acid.

3 ced by a synthetic viral mimic, polyinosinic-polycytidylic acid.

4 inducing viral infections or by polyinosinic:polycytidylic acid.

5 llowing brief pretreatment with polyinosinic:polycytidylic acid.

6 tivation with the TLR3 agonist, polyinosinic:polycytidylic acid.

7 by TNF, lipopolysaccharide and polyinosinic-polycytidylic acid.

8 s by both transfected PRNAs and polyinosinic-polycytidylic acid.

9 n of low doses of a TLR ligand, polyinosinic-polycytidylic acid.

10 eally at gestational day 9 with polyinosinic:polycytidylic acid.

11 opolysaccharide, IFN-gamma, and polyinosinic-polycytidylic acid.

12 h an analogous acycloguanosine derivative on polycytidylic acid.

13 ogether with anti-CD40 mAbs and polyinosinic-polycytidylic acid.

14 tar Furth) strains induced with polyinosinic:polycytidylic acid.

15 mplex following stimulation with polyinosine-polycytidylic acid.

16 cells following activation with polyinosinic-polycytidylic acid.

17 ic cells upon inducing Cre with polyinosinic-polycytidylic acid.

18 in response to the viral mimic, polyinosinic:polycytidylic acid.

19 with LPS (a bacterial mimic) or polyinosinic-polycytidylic acid (a viral mimic), M-TRAF3(-/-) mice ex

20 study that TLR3 stimulation by polyinosinic-polycytidylic acid, a double-stranded RNA analog, suppre

21 n response to the dsRNA agonist polyinosinic-polycytidylic acid, a subset of which were modestly regu

22 study, we describe a model of polyinosinic: polycytidylic acid-accelerated lupus nephritis in NZB/W

23 Polyinosinic-polycytidylic acid activated IFN regulatory factor 3 dim

24 50 nucleotides long as well as polyinosinic-polycytidylic acid activated the RNA-dependent protein k

25 diminished the cytotoxicity of polyinosinic-polycytidylic acid-activated natural killer cells agains

26 ty as well as an enhancement of polyinosinic-polycytidylic acid activation of TLR3.

27 iciency in activation following polyinosinic:polycytidylic acid administration in vivo.

28 analogue of viral nucleic acid, polyinosinic-polycytidylic acid, also induced IL-6-dependent glucocor

29 velop IDDM after treatment with polyinosinic:polycytidylic acid and a cytotoxic anti-RT6.1 monoclonal

30 WAG-rnu/rnu rats treated with polyinosinic: polycytidylic acid and a monoclonal antibody to preclude

31 e diabetes after treatment with polyinosinic:polycytidylic acid and an antibody that depletes ART2(+)

32 ated ex vivo with TLR agonists, polyinosinic-polycytidylic acid and CpG, to prime naive CD4 T cells i

33 ly be induced by treatment with polyinosinic:polycytidylic acid and depletion of RT6+ T-cells.

34 one marrow with the viral mimic polyinosinic:polycytidylic acid and found a significant reduction of

35 We found that TLR3-ligand polyinosinic-polycytidylic acid and human rhinovirus infection induce

36 The synthetic dsRNA analog polyinosinic-polycytidylic acid and infection with live virus were us

37 inflammatory stimuli, including polyinosinic polycytidylic acid and LPS.

38 immunostimulatory nucleic acid polyinosinic:polycytidylic acid and UV light irradiation, linking RNa

39 epitope M282-90, a TLR agonist (polyinosinic-polycytidylic acid), and a costimulatory anti-CD40 Ab.

40 rs upon in vivo activation with polyinosinic:polycytidylic acid, and have poor survival in ex vivo cy

41 Sendai virus, the dsRNA mimetic polyinosinic-polycytidylic acid, and LPS all activated differentiatio

42 In vivo administration of CpG, polyinosinic-polycytidylic acid, and Pam(3)CSK(4) in combination with

43 ed by crude LPS, peptidoglycan, polyinosinic:polycytidylic acid, and rIFN-gamma in cell lines and pri

44 vaccine with the TLR3 agonist, polyinosinic-polycytidylic acid, and TLR9 agonist, CpG, reduced tumor

45 ral double-stranded RNA (dsRNA) polyinosinic-polycytidylic acid, and type-II interferon-gamma (IFNgam

46 rs of IFN-lambda in response to polyinosinic-polycytidylic acid but are similar to CD1c(+) DC in thei

47 ) DC were strongly activated by polyinosinic-polycytidylic acid but not LPS, and conversely for MoDC.

48 e synthetic double-stranded RNA polyinosinic-polycytidylic acid causes a PPI deficit in the offspring

49 Prenatal exposure to polyinosinic:polycytidylic acid causes an imbalanced expression of th

50 Downregulation upon polyinosinic-polycytidylic acid challenge and expression by crypt cel

51 FN-alpha/beta induced by either polyinosinic-polycytidylic acid complex or by lymphocytic choriomenin

52 -exposed mice intranasally with polyinosinic-polycytidylic acid condensed with poly-l-lysine and carb

53 We demonstrated that polyinosinic:polycytidylic acid consistently up-regulated both B7-2 a

54 ated with lipopolysaccharide or polyinosinic-polycytidylic acid coordinate with constitutively active

55 d the interferon-inducing agent polyinosinic:polycytidylic acid did not induce allograft rejection, s

56 We have recently shown that the polycytidylic acid-directed polymerization of guanosine

57 ycoloyl glycerol liposomes with polyinosinic:polycytidylic acid electrostatically adsorbed to the sur

58 sure to the viral-like adjuvant polyinosinic:polycytidylic acid enhanced anti-FVIII antibody formatio

59 etic resonance (NMR) evidence suggested that polycytidylic acid forms a left-handed helix.

60 le- and single-stranded polynucleotides, but polycytidylic acid greatly enhances activity and also pr

61 with the IFN-alpha/beta inducer polyinosine polycytidylic acid (hereafter 'poly(I:C)') inhibited egr

62 peptide-, double-stranded RNA (polyinosinic-polycytidylic acid)-, HIV-1 Tat-, 1-methyl-4-phenylpyrid

63 ed in macrophages after LPS and polyinosinic:polycytidylic acid in vitro.

64 ipopeptide-2, or a TLR3 ligand, polyinosinic-polycytidylic acid, increased Cox-2 mRNA and protein and

65 tivation by TLR ligands LPS and polyinosinic-polycytidylic acid induced a time-dependent increase of

66 tural killer cell activation by polyinosinic-polycytidylic acid induced cell death to activated hepat

67 Notably, polyinosinic:polycytidylic acid induced nuclear localization of iNOS,

68 In contrast, a synthetic dsRNA, polyinosinic polycytidylic-acid, induced CD11c(+) DC, but not pre-DC2

69 ere markedly less responsive to polyinosinic-polycytidylic acid-induced acute proliferative signals.

70 Polyinosinic-polycytidylic acid-induced antiviral genes were identifi

71 nthetic dsRNA-based viral mimic polyinosinic:polycytidylic acid-induced expression of proinflammatory

72 tion receptors was required for polyinosinic-polycytidylic acid-induced IFN-alpha/beta production and

73 Compound II inhibited polyinosinic-polycytidylic acid-induced immune activation in vitro an

74 rtantly, we discovered that the polyinosinic-polycytidylic acid-induced increase in production of IFN

75 e transfused in the presence of polyinosinic:polycytidylic acid-induced inflammation.

76 D138N are resistant to TNF- and polyinosinic-polycytidylic acid-induced necroptosis in vitro, and Rip

77 A defect in polyinosinic-polycytidylic acid-induced TLR3 responses can be detecte

78 rophages; however, priming with polyinosinic-polycytidylic acid induces it and confers needle protein

79 ad, challenge of TM with LPS or polyinosinic-polycytidylic acid induces MAPK, AP-1, and CREB signalin

80 ng anti-CD40 Ab and TLR3 ligand polyinosinic-polycytidylic acid induces protective responses against

81 we show that TLR3 activation by polyinosinic:polycytidylic acid induces up-regulation of microRNA-29b

82 mmatory cytokines in response to polyinosine-polycytidylic acid, influenza A, and reovirus.

83 s infection or after repetitive polyinosinic-polycytidylic acid injection.

84 ection of lipopolysaccharide or polyinosinic:polycytidylic acid into mice, mimicking bacterial and vi

85 to respond to stimulation with polyinosinic:polycytidylic acid is abolished when its interaction wit

86 TLR3 activation with polyinosinic-polycytidylic acid led to comparable or even higher cyto

87 Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNbeta expression in P

88 s to stimulation with Pam3CSK4, polyinosinic-polycytidylic acid, LPS, and ODN2006, respectively.

89 cer cells, we demonstrated that polyinosinic:polycytidylic acid-mediated activation of TLR3 induces m

90 y sensitizes cells to cytosolic polyinosinic/polycytidylic acid-mediated induction of type I IFN.

91 ten allograft survival, whereas polyinosinic:polycytidylic acid mediates its effects through a TLR3-i

92 e observed protective effect of polyinosinic-polycytidylic acid on liver fibrosis was diminished thro

93 Treatment with polyinosinic-polycytidylic acid or a combination of monosodium urate

94 and then exposed them to either polyinosinic:polycytidylic acid or a diabetogenic virus to induce dia

95 following the administration of polyinosinic:polycytidylic acid or allogeneic cells (graft versus hos

96 n induced by LPS, as opposed to polyinosinic:polycytidylic acid or cytosine-phosphate-guanine, is rob

97 iet and in mice given low-level polyinosinic:polycytidylic acid or dextran sodium sulfate to induce c

98 DCs stimulated by polyinosinic acid-polycytidylic acid or IFN-beta, another known inducer of

99 Moreover, treatment with polyinosinic-polycytidylic acid or interferon gamma enhanced the cyto

100 after TLR stimulation with polyinosinic acid-polycytidylic acid or LPS underwent apoptosis, which was

101 sociated Ag upon stimulation by polyinosinic-polycytidylic acid or R848, likewise to what was reporte

102 temically with the TLR3 agonist polyinosinic:polycytidylic acid or were given subcutaneously, activat

103 ning adapter inducing IFN-beta (polyinosinic-polycytidylic acid) or MyD88 (imiquimod), demonstrating

104 engagement of either the TLR3 (polyinosinic-polycytidylic acid) or TLR4 (LPS) receptor.

105 In the absence of polyinosinic:polycytidylic acid, or in the presence of antagonists of

106 infection, cellular exposure to polyinosinic-polycytidylic acid, or TBK1 overexpression.

107 phage-activating lipopeptide-2, polyinosinic-polycytidylic acid, or UVB (15 mJ/cm(2)), but it did not

108 We show that IFN-alpha and polyinosinic:polycytidylic acid (p-I:C) synergize with the "classical

109 on with the Th1-biased adjuvant polyinosinic:polycytidylic acid (pI:C).

110 was induced in C57BL/6 mice by polyinosinic-polycytidylic acid (PIC) injected during embryonic days

111 ula Yeast RNA (TYRNA)(640 nm), polyinosinic: polycytidylic acid (pIC)(680 nm), or splice switching ol

112 whether retinoic acid (RA) and polyinosinic:polycytidylic acid (PIC), an inducer of interferons, can

113 Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like receptor 3 agonist)

114 Polyinosine-polycytidylic acid [pIC] is a synthetic dsRNA that acts

115 exhibited impaired responses to polyinosine-polycytidylic acid (pIpC) and reduced production of infl

116 noviocytes were stimulated with polyinosinic-polycytidylic acid (poly [I-C]) after transfection with

117 of TLR3 by the synthetic ligand polyinosine:polycytidylic acid (poly I:C) or by mRNA rapidly causes

118 Polyinosinic-polycytidylic acid (Poly I:C) or IFN-gamma treatment inh

119 Polyinosinic-polycytidylic acid (poly I:C) or IFN-gamma treatment inh

120 We investigated the role of polyriboinosinic:polycytidylic acid (poly I:C), a replication-competent v

121 Polyinosinic:polycytidylic acid (poly I:C), a synthetic analog of dou

122 p diabetes after treatment with polyinosinic:polycytidylic acid (poly I:C), a synthetic double-strand

123 strocyte primary cultures using polyinosinic-polycytidylic acid (poly I:C), a synthetic ds-RNA molecu

124 Polyinosinic-polycytidylic acid (poly I:C), a TLR3 ligand, is current

125 ysaccharide, a TLR4 ligand; and polyinosinic:polycytidylic acid (poly I:C), a TLR3 ligand; but not li

126 prime T cells: the TLR3 ligand, polyinosinic:polycytidylic acid (poly I:C), and immunostimulatory com

127 reated timed-pregnant mice with polyinosinic:polycytidylic acid (Poly I:C), which simulates a viral i

128 t with the synthetic TLR3 ligand polyinosine-polycytidylic acid (poly I:C).

129 virus or with the viral mimetic polyinosinic:polycytidylic acid (poly I:C).

130 cytokine induction elicited by polyinosinic:polycytidylic acid (poly I:C; a synthetic dsRNA) in mous

131 slets with dsRNA in the form of polyinosinic-polycytidylic acid (poly IC) and IFN-gamma resulted in i

132 d the effect of the TLR3 ligand polyinosinic-polycytidylic acid (poly IC) on CD8 T cell immunity and

133 The synthetic dsRNA molecule polyinosinic-polycytidylic acid (poly IC) stimulates beta-cell DNA da

134 ceptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most effective ad

135 sRNA) (in the form of synthetic polyinosinic-polycytidylic acid (poly IC)) on islet expression of ind

136 dsRNA [polyinosinic:polycytidylic acid (poly IC)]-stimulated inducible nitri

137 cells (MASM) treated with polyinosinic acid-polycytidylic acid (poly(I,C)), a double-stranded RNA th

138 ) nanoparticles adjuvanted with polyinosinic:polycytidylic acid (poly(I:C) as an adjuvant (Vaccine-NP

139 the Toll-like receptor ligands polyinosinic-polycytidylic acid (poly(I:C)) and flagellin.

140 response to TLR3 activation by polyinosinic-polycytidylic acid (poly(I:C)) and related agonists in h

141 ed RNA and the synthetic analog polyinosinic:polycytidylic acid (poly(I:C)) bind and activate TLR3.

142 ia responded to synthetic dsRNA polyinosinic-polycytidylic acid (poly(I:C)) by increasing TLR3 and IF

143 tion of macrophage responses to polyinosinic-polycytidylic acid (poly(I:C)) resulting from three inde

144 IFN-beta expression elicited by polyinosinic-polycytidylic acid (poly(I:C)) treatment or IFN-alpha be

145 imulation by the dsRNA analogue polyinosinic:polycytidylic acid (poly(I:C)) was dependent on TLR3 and

146 asts, the synthetic TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)), a dsRNA analog, caused d

147 is activated by viral dsRNA and polyinosinic-polycytidylic acid (poly(I:C)), a synthetic mimetic of v

148 Polyinosine-polycytidylic acid (poly(I:C)), a Toll-like receptor 3 (

149 Polyinosinic-polycytidylic acid (poly(I:C)), an analog of viral dsRNA

150 igands tested, the TLR3 ligand, polyinosinic/polycytidylic acid (Poly(I:C)), most highly increased fi

151 e induction by a viral mimetic, polyinosinic-polycytidylic acid (poly(I:C)), of the endothelial cell-

152 mice showed reduced responses to polyinosine-polycytidylic acid (poly(I:C)), resistance to the lethal

153 such as LPS, lipoteichoic acid, polyinosinic-polycytidylic acid (poly(I:C)), TNF-alpha, and type I an

154 d in the presence or absence of polyinosinic-polycytidylic acid (poly(I:C)), which elicits RLR accumu

155 or (TNF), lipopolysaccharide or polyinosinic:polycytidylic acid (poly(I:C))-induced necroptosis and i

156 Anti-CD40 also increased polyinosinic-polycytidylic acid (poly(I:C))-inducible IFN-alpha by 5-

157 s by influenza-infected DCs and polyinosinic:polycytidylic acid (poly(I:C))-treated DCs was distingui

158 ge cells stimulated with LPS or polyinosinic-polycytidylic acid (poly(I:C)).

159 ot translocate to lipid rafts by polyinosine-polycytidylic acid (poly(I:C)).

160 de (LPS, bacterial antigen) and polyinosinic-polycytidylic acid (poly(I:C), viral antigen) would decr

161 oli (TLR4), lipoprotein (TLR2), polyinosinic-polycytidylic acid (poly-IC) (TLR9), and their combinati

162 e responses upon challenge with polyinosinic-polycytidylic acid (poly-IC).

163 As polyinosinic-polycytidylic acid (poly[I:C]), which mimics double-stra

164 with the known IFN inducer polyinosinic acid-polycytidylic acid (poly[I]-poly[C]) resulted in an incr

165 at viral-like inflammation with polyinosinic polycytidylic acid [poly (I:C)] significantly enhances R

166 Polyinosinic-polycytidylic acid [Poly (I:C)], a dsRNA receptor ligand

167 nstrate for the first time that polyinosinic-polycytidylic acid [poly (I:C)], a synthetic dsRNA analo

168 synthetic double-stranded RNA (polyinosinic:polycytidylic acid [poly IC] stabilized with poly-L-lysi

169 ha/beta interferon induction by polyinosinic-polycytidylic acid [poly(I-C)] treatment efficiently eli

170 with the IFN-alpha/beta inducer polyinosinic-polycytidylic acid [poly(I-C)].

171 ycan (PGN; a TLR 2 agonist) and polyinosinic-polycytidylic acid [poly(I:C); a TLR3 agonist], modeling

172 smooth muscle cells (VSMCs) to polyinosinic:polycytidylic acid [poly(I:C)] and was necessary for inf

173 t CD8 T-cell function; however, polyinosinic:polycytidylic acid [poly(I:C)] can also suppress autoimm

174 e born to mothers injected with polyinosinic:polycytidylic acid [poly(I:C)] during pregnancy as a mod

175 tion induced by the viral mimic polyinosinic-polycytidylic acid [poly(I:C)] in primary human lung epi

176 like receptor 3 (TLR-3) agonist polyinosinic:polycytidylic acid [poly(I:C)] in the SN of adult rats.

177 Polyinosinic-polycytidylic acid [poly(I:C)] is a known inducer of IFN

178 was to evaluate the activity of polyinosinic-polycytidylic acid [poly(I:C)] on IL-17A production by C

179 Application of polyinosinic-polycytidylic acid [poly(I:C)] or LPS induces production

180 epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and

181 factor 3 in response to LPS and polyinosinic-polycytidylic acid [poly(I:C)] stimulus, corroborating t

182 ) mice primed with TLR3 agonist polyinosinic:polycytidylic acid [poly(I:C)] to induce pro-caspase-11

183 TLR3 signaling through LPS and polyinosinic:polycytidylic acid [poly(I:C)] treatments resulted in ra

184 ) infection and the TLR3 ligand polyinosinic-polycytidylic acid [poly(I:C)] were used to activate inn

185 ioning with the synthetic dsRNA polyinosinic-polycytidylic acid [poly(I:C)], a mimetic of viral RNA,

186 nd was mimicked by injection of polyinosinic-polycytidylic acid [poly(I:C)], an inducer of type I int

187 stration of the synthetic dsRNA polyinosinic:polycytidylic acid [poly(I:C)], but not lipopolysacchari

188 otent inducer of IFN-alphabeta, polyinosinic-polycytidylic acid [poly(I:C)], led to the depletion of

189 ns were resiquimod (R-848) plus polyinosinic-polycytidylic acid [Poly(I:C)], R-848 plus LPS, Pam3CSK4

190 of cells or fish with the dsRNA polyinosinic-polycytidylic acid [poly(I:C)], which induces IFNs via t

191 oligonucleotide [Poly(dT)], and polyinosinic-polycytidylic acid [Poly(I:C)].

192 ide ISA51 with or without TLR3 (polyinosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipi

193 n combination, synthetic dsRNA (polyinosinic-polycytidylic acid, poly(I-C)) and interferon (IFN)-gamm

194 double-stranded RNA (synthetic polyinosinic-polycytidylic acid; poly(I-C)) on macrophage expression

195 Activation of TLR3 by polyinosinic-polycytidylic acid (polyI:C) leads to induction of multi

196 ng of fetal loss in response to polyinosinic:polycytidylic acid (polyI:C), a viral mimic and an induc

197 tic double-stranded RNA ligand, polyinosinic-polycytidylic acid (polyI:C), leads to decreased acetami

198 ion (MIA) during pregnancy with polyinosinic:polycytidylic acid (polyI:C).

199 infection or viral mimic [polyinosinic acid:polycytidylic acid (polyI:C)] treatment of human colon M

200 employed the viral RNA mimetic (polyinosinic-polycytidylic acid [polyI:C]) to emulate viral infection

201 Polyinosinic-polycytidylic acid (PolyIC), a "mimic" of double-strande

202 ion and treatment of cells with polyinosinic-polycytidylic acid (polyIC; a dsRNA mimetic that acts as

203 as CpG oligodeoxynucleotide and polyinosinic:polycytidylic acid primarily stimulated Th1 cells.

204 crease in spleen in response to polyinosinic-polycytidylic acid-promoted hepatitis.

205 clusively upon stimulation with polyinosinic-polycytidylic acid, R848, and CL075 ligands.

206 Challenge with polyinosinic-polycytidylic acid results in a rapid and strong downreg

207 nd MyD88-independent receptors (polyinosinic:polycytidylic acid signaling via TLR3 or ds break-DNA si

208 esponses via active delivery of polyinosinic-polycytidylic acid sodium salt (poly I:C) to target Toll

209 gamma, rmIFN-alpha, rmIL-4, and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethy

210 very 3 weeks with intramuscular polyinosinic-polycytidylic acid stabilized by lysine and carboxymethy

211 synthetic double-stranded RNA (polyinosinic:polycytidylic acid stabilized with poly-l-lysine) during

212 synthetic double-stranded RNA (polyinosinic:polycytidylic acid stabilized with poly-L-lysine) was de

213 data indicate that CpG DNA and polyinosinic-polycytidylic acid stimulate different types of cells to

214 w trout RTG-2 and RTS-11 cells, polyinosinic-polycytidylic acid stimulation resulted in early activat

215 In contrast, polyinosinic:polycytidylic acid strongly represses CpG's as well as i

216 monomycolyl glycerol analog and polyinosinic-polycytidylic acid) that efficiently induces CD4 Th cell

217 f the inhaled viral TLR ligands polyinosinic-polycytidylic acid (TLR3) and resiquimod (TLR7/8) on sen

218 the TLR agonists LPS (TLR4) or polyinosinic:polycytidylic acid (TLR3) to mice treated with costimula

219 S (TLR4), peptidoglycan (TLR2), polyinosinic-polycytidylic acid (TLR3), CpG DNA (TLR9), and infection

220 ion, but selectively spared the polyinosinic-polycytidylic acid/TLR3 pathway.

221 cted with TLR2 (Pam3Cys), TLR3 (polyinosinic:polycytidylic acid), TLR4 (LPS), or TLR9 (CpG) agonists.

222 sis after stimulation with LPS, polyinosinic-polycytidylic acid, TNF-alpha, or IFN-beta in the presen

223 in the presence of anti-CD40 or polyinosinic:polycytidylic acid to induce DC maturation.

224 ors and innate immune activator polyinosinic:polycytidylic acid to induce endothelial cells.

225 However, KCs isolated from polyinosinic:polycytidylic acid-treated mice expressed significantly

226 Polyinosinic-polycytidylic acid treatment also ameliorated liver fibr

227 Polyinosinic-polycytidylic acid treatment of RAG(-/-) mice transplant

228 ry head kidney leukocytes after polyinosinic-polycytidylic acid treatment, whereas a moderate increas

229 type mice with the IFN-I inducer polyinosine polycytidylic acid triggered HS expression at the B cell

230 cytosine-phosphate-guanine, or polyinosinic:polycytidylic acid) using flow cytometry and measurement

231 DHX9 could specifically bind polyinosine-polycytidylic acid via its double-strand RNA binding mot

232 DHX15 specifically bound polyinosine-polycytidylic acid via its helicase C-terminal domain.

233 s in hDEC205 transgenic mice, if polynocinic polycytidylic acid was coadministered as an adjuvant.

234 he Toll-like receptor 3 ligand, polyinosinic-polycytidylic acid, was used to activate innate immunity

235 polyuridine) and dsRNA viruses (polyinosinic-polycytidylic acid) were significantly weaker (2- to 3-f

236 transfusions in the presence of polyinosinic:polycytidylic acid, whereas anti-hGPA levels increased i

237 leukocytes when stimulated with polyinosinic:polycytidylic acid, whereas group II IFN was up-regulate

238 infected mice with a complex of polyinosinic-polycytidylic acid with poly-L-lysine and carboxymethyl